Key Statement - Roche's statement on Tocilizumab (Actemra) supplies

We have observed an unprecedented demand for Tocilizumab (Brand: Actemra) given the significant increase in Covid cases across India in the last few weeks.

We are responding to this situation with supplies over this and the coming weeks to meet the immediate emergency demand. However, we are mindful that the current unprecedented demand may far exceed the supplies we can provide at this moment.

We are working urgently to increase manufacturing capacity and supply by ramping up our own production network, as well as actively collaborating with external partners to maximize production of Actemra wherever possible with the goal of increasing its availability. This should enable us to meet future demand in a fluid and hard to predict environment.

In India we have partnered with Cipla for the marketing and distribution of Tocilizumab (Actemra)

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, visit us atOR please call the Roche India Safety Unit onor E-mail us at

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePersonalised HealthcareSolutionsRoche careersMediaPrivacy policyLegal statement